Protocathecuic acid for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
Protocathecuic acid may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed protocathecuic acid in detail.
, Investigation of The Inhibition of SARS-CoV-2 Spike RBD and ACE-2 Interaction by Phenolics of Propolis Extracts, Journal of Apitherapy and Nature, doi:10.35206/jan.1471090
The molecules that consist of propolis are generally polyphenols, and they have many activities such as antiviral, antibacterial and antifungal activities. In this study, it is aimed to investigate the inhibiting capacity of the interaction between ACE-2 and Spike RBS by propolis samples belong to three different cities (Trabzon, Kocaeli, Kırıkkkale). After determining the propolis sample exhibiting the highest inhibition effect, the phenolics within this sample were identified, individual assessments of the inhibition effects of each phenolic compound were conducted with Spike S1 (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit and supported by docking studies in silico. Propolis sample with the highest inhibition effect was determined as 'Kocaeli'. Then, the pure molecules known to be present in Kocaeli propolis were tested and found that p-OH benzoic acid, syringic acid, ferulic acid and gallic acid did not have any inhibitory effects on the Spike S1 (SARS-CoV-2): ACE2 interaction. The substances with the greatest inhibitory effect are; protocathecuic acid, caffeic acid, p-coumaric acid with the inhibition of 62.29%, 58.34%, 59.20%, respectively. The lowest IC50 value of the flavonoids was found to be 0.89 mM with caffeic acid. Over all in silico, in vitro experiments, and MTT analyses conducted in the literature have demonstrated that caffeic acid and protocatechuic acid can be used as a highly active compound against COVID-19.